News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
510,890 Results
Type
Article (43838)
Company Profile (123)
Press Release (466929)
Section
Business (144282)
Career Advice (2366)
Deals (27853)
Drug Delivery (97)
Drug Development (67508)
Employer Resources (147)
FDA (15440)
Job Trends (11896)
News (262161)
Policy (29511)
Tag
Academia (2280)
Africa (665)
Alliances (35603)
Alzheimer's disease (1194)
Antibody-drug conjugate (ADC) (61)
Approvals (15353)
Arizona (121)
Artificial intelligence (57)
Asia (30189)
Australia (5259)
Bankruptcy (299)
Best Places to Work (8847)
Biosimilars (68)
Biotechnology (74)
C2C Services and Suppliers (51923)
California (1499)
Canada (664)
Cancer (385)
Career advice (1973)
Cell therapy (119)
China (102)
Clinical research (52570)
Collaboration (108)
Colorado (57)
Compensation (68)
Connecticut (64)
COVID-19 (2495)
Cystic fibrosis (67)
Data (203)
Diabetes (77)
Diagnostics (4937)
Drug pricing (77)
Earnings (55998)
Employer resources (132)
Europe (72995)
Events (72991)
Executive appointments (111)
FDA (15622)
Florida (226)
Funding (105)
Gene therapy (97)
GLP-1 (571)
Government (3751)
Healthcare (14631)
Hotbed/Location (337112)
Illinois (173)
Indiana (108)
Infectious disease (2522)
Inflammatory bowel disease (82)
Interviews (442)
IPO (13691)
Job creations (3145)
Job search strategy (1655)
Kansas (75)
Layoffs (427)
Legal (6872)
Lung cancer (94)
Manufacturing (84)
Maryland (336)
Massachusetts (1237)
Medical device (10932)
Medtech (10935)
Mergers & acquisitions (14023)
Metabolic disorders (269)
Michigan (91)
Minnesota (162)
Neuroscience (1330)
New Jersey (450)
New York (470)
NextGen Class of 2024 (4950)
Non-profit (3147)
North Carolina (522)
Northern California (699)
Obesity (165)
Ohio (79)
Opinion (178)
Patents (65)
Pennsylvania (490)
People (41375)
Phase I (15616)
Phase II (22731)
Phase III (18806)
Pipeline (102)
Policy (61)
Postmarket research (2185)
Preclinical (6308)
Rare diseases (126)
Real estate (4239)
Recruiting (58)
Regulatory (19819)
Research institute (2045)
Resumes & cover letters (397)
South America (1024)
Southern California (618)
Startups (2730)
Texas (181)
United States (6819)
Vaccines (530)
Washington State (212)
Weight loss (160)
Date
Today (126)
Last 7 days (549)
Last 30 days (1930)
Last 365 days (32749)
2024 (22456)
2023 (34981)
2022 (45058)
2021 (48501)
2020 (45513)
2019 (36210)
2018 (27398)
2017 (27806)
2016 (25804)
2015 (27973)
2014 (21774)
2013 (17792)
2012 (18963)
2011 (19382)
2010 (17504)
510,890 Results for "symphogen a s".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Servier Completes the Acquisition of Symphogen
Servier, an independent international pharmaceutical company, today announced that it has completed the acquisition of Symphogen A/S. Symphogen will now function as Servier’s antibody center of excelle
June 4, 2020
·
2 min read
Drug Development
Psychosis: The Other Big Alzheimer’s Therapeutic Target
While disease-modifying therapies largely steal the spotlight in Alzheimer’s drug development, several companies are working to solve this less-discussed but disruptive facet of the illness.
March 27, 2024
·
7 min read
·
Sruthi S. Balakrishnan
Regulatory
AstraZeneca’s Imfinzi Scores Lung Cancer Wins With FDA’s NSCLC Approval, SCLC Priority Review
Imfinzi’s perioperative approval comes after both the FDA’s staffers and a panel of external experts expressed concerns about overtreatment when using the PD-L1 blocker both before and after surgery.
August 16, 2024
·
2 min read
·
Tristan Manalac
Regulatory
EU Regulatory Panel Recommends Against Approval of Eisai, Biogen’s Leqembi for Alzheimer’s
The European Medicines Agency’s Committee for Medicinal Products for Human Use found that Leqembi’s benefits do not outweigh the risks of severe side effects associated with the treatment.
July 26, 2024
·
2 min read
·
Tyler Patchen
Immunology and inflammation
GSK Builds Nucala’s COPD Case With Phase III Win
If approved in chronic obstructive pulmonary disease, Nucala will compete with Verona’s Ohtuvayre and—pending a potential approval later this month—Sanofi and Regeneron’s blockbuster Dupixent.
September 6, 2024
·
2 min read
·
Tristan Manalac
Patents
Patent Thickets in Federal Government’s Crosshairs as Election 2024 Looms
Congress, the Federal Trade Commission and the U.S. Patent and Trademark Office are all targeting Big Pharma’s practice of filing multiple, overlapping patents that stifle generic and biosimilar competition.
August 28, 2024
·
7 min read
·
Greg Slabodkin
Supply chain
Novo’s Ozempic to Remain in Shortage Into Q4 as Supply Woes Continue
Novo Nordisk’s continuing supply problems for semaglutide come as the pharma tries to expand the drug’s indication, opening it up to more patients—and potentially to heavier production pressures.
September 3, 2024
·
2 min read
·
Tristan Manalac
GLP-1
UK’s MHRA Finds No Risk of Suicidal Ideation, Self-Harm With GLP-1 Drugs
Like its U.S. and European counterparts, Britain’s Medicines and Healthcare Products Regulatory Agency found no conclusive link between the use of GLP-1s and a heightened risk of suicidal and self-injury thoughts.
September 5, 2024
·
2 min read
·
Tristan Manalac
Weight Loss
Novo’s Obesity Pill Yields ‘Remarkable’ 13% Weight Loss, Investigators Say
On the heels of Terns’ positive Phase I results that analysts compared with Lilly’s and Pfizer’s weight loss pills in development, Novo Nordisk showcased more details about its own oral candidate.
September 11, 2024
·
2 min read
·
Annalee Armstrong
FDA
FDA Approves Eli Lilly’s Donanemab to Treat Alzheimer’s Disease
Donanemab, which will be marketed as Kisunla, will compete with Biogen and Eisai’s Leqembi.
July 2, 2024
·
4 min read
·
Tyler Patchen
1 of 51,089
Next
